Better Buy: GlaxoSmithKline vs. Pfizer

GlaxoSmithKline (NYSE: GSK) and Pfizer (NYSE: PFE) have both been in the headlines lately as they lead the way in the race to develop a coronavirus vaccine. While it hasn't been an easy year for many household names in the big-pharma space, these two companies entered the coronavirus bear market from a position of strength and have continued to show consistent, healthy gains since the stock market's low in March. 

It's clear that both companies have a lot going for them, but which is the better buy? 

Image source: Getty Images.

Continue reading

Source Fool.com